About
Summary
I am Shambhunath Bose, Ph.D. with extensive experience in Life Sciences, Biotechnology, Cell & Molecular Biology, Biochemistry, Pharmaceuticals, Pharmacology, Drug Discovery both in academics and industries.
Present Occupation (March 2022-Till date): Professor, Department of Life Sciences, Graphic Era University, Dehradun.
July 2021-January 2022: Professor (Academics & Research), Department of Life Sciences, Sri Sathya Sai University for Human Excellence, Karnataka.
January 2019-June 2021: Freelance Scientific Consultants- Dongguk University, Gyeonggi-do, South Korea & BexPharm Healthcare Ltd., Seongdong-gu, Seoul, South Korea.
March 2016-December 2018: Chief, Research at NosQuest, Inc. (a Molecular Diagnostic Company), South Korea.
2009- 2016: Non-native Faculty, Dongguk University, Seoul, South Korea.
2008–2009: Worked with Jubilant Biosys Ltd., a renowned Research-based Drug Discovery Company in Bangalore, India as Associate Director, Biology at senior management level.
2004–2008: Research Manager in the R&D of a proteomics based and research oriented company in South Korea, originally established by Green Cross Corporation, a renowned Pharmaceutical company in South Korea.
2000-2004: Post Doctorate Fellow, Department of Biochemistry, Institute of Biomedicine, University of Helsinki, Helsinki, Finland.
1998-2000: Worked as a Senior Scientist, Biology, in the New Drug Discovery Group of Zydus-Cadila Ltd., a Pharmaceutical and Biotechnology company at Ahmedabad, India having a strong global presence.
1995-1998: Worked as a Research Scientist, Biology, in the New Drug Discovery Group of Wockhardt Ltd., a Pharmaceutical and Biotechnology company at Aurangabad, India having a strong global presence.
Ph.D. in Life-Science. with a prestigious fellowship (Dr. K. S. Krishnan, DAE) from Bhabha Atomic Research Centre (BARC), Trombay, India.
Besides, I have 75 publications (mostly SCOPUS-indexed) in reputed international peer-reviewed Journals/Books with the highest impact factor of 12.0. Additionally, I have also three South Korean Patents.
I also worked as New Product Consultant (NPC) for ‘Small Molecule Tools in Cell Biology’, Sigma-Aldrich Corporation, St. Louis, MO, USA. (https://www.sigmaaldrich.com/).
Besides, I worked as an External Expert and writer for the ‘Future Trends Study of Obesity,' in Sterling Brands, Los Angeles, CA, USA. (https://www.sterlingbrands.com/)
Positions
Foreign Faculty Nov 2009 -
University website: http://www.dongguk.edu
Research and supervision of postgraduate thesis.
Research on the following topics:
Development of therapeutic approaches to combat inflammation especially, neuroinflammation, diabetes and obesity.
Elucidation of the impact of single nucleotide polymorphisms (snps) on the anti-obesity impact of herbal-based medicines.
Detailed investigations on the influence of gut microbial-host interaction on the onset and progression of metabolic disorders at molecular levels using Real-time PCR, microarray, PCR-denaturing gradient gel electrophoresis fingerprinting, and pyrosequencing, as well as different bioinformatics tools for functional annotation and analyses of correlation, principal coordinate, and clustering.
Development of therapeutic approaches that improves memory impairment and reduces Aß level in the Alzheimer’s disease.
Achievements:
Writing and publishing papers in the following journals:
Scientific Reports (Nature Publication Group), Molecular Nutrition & Food Research, PLoS ONE, Clinical Nutrition, Food Chemistry, Biomolecules & Therapeutics, Food & Function, Journal of Ethnopharmacology, Journal of Ginseng Research, Evidence-Based Complementary and Alternative Medicine, Journal of Medicinal Food, Archives of Pharmacal Research, Bulletin of the Korean Chemical Society, BioChip Journal, European Journal of Integrative Medicine, Journal of Korean Medicine Rehabilitation, Journal of Korean Medicine for Obesity Research, Journal of the Korean Society of Food Science and Nutrition, Journal of Society of Korean Medicine for Obesity Research, Journal of Oriental Rehabilitation Medicine.
Selected International Presentations:
Shambhunath Bose, C. Park, S. Kim, J. S. Cho. Involvement of PI3Kγ in the CCL2-
induced phosphorylation of ERK1/2 and p90RSK in the primary culture of rat cortical
cells. 2014 Spring International Convention of the Pharmaceutical Society of
Korea, April 18th, 2014. Seoul, South Korea, Section P1-41.
Md. Moniruzzaman, Shambhunath Bose, Y. W. Chin, J. S. Cho. Anti-inflammatory
effects of Physalis alkekengi fruit through inhibition of PI3K/Akt and MAP Kinase
pathways in LPS-induced BV2 microglial cells. 2014 Fall International Convention
of the Pharmaceutical Society of Korea. October 25th, 2014, Seoul, South
Korea, Section P1-30.
Shambhunath Bose, and J.S. Cho. Evaluation of impact of CCL2 on vital Signaling
cascades in microglial cells using BV2 cell line as a model. 2013 Fall International
Conference, The Pharmaceutical Society of Korea, October 17-October 18,
2013, Chungbuk Osong CV Center Foundation, Osong, South Korea.
Shambhunath Bose. Possible therapeutic approaches to combat obesity using
herbal-based formulations. The 16th International Congress of Oriental Medicine
(ICOM). The future of Medicine, Traditional Medicine, September 14 –
September 16, 2012, Seoul, South Korea.
J. E. Jung, S. J. Lee, Shambhunath Bose, and H. Kim. Protective effect of mixed
fermented dietary herbal preparations against LPS and neomycin insult. 40th
Anniversary: Functional Fusion and Systemic Approaches to Future Foods,
October 31 – November 2, 2011, BEXCO, Busan, South Korea
Associate Director Oct 2008 - Aug 2009
The company websie: http://www.jubilantbiosys.com
Involved in integrated drug discovery program in collaboration with top global pharmaceutical companies like AstraZeneca, Eli Lilly, Endo Pharmaceuticals, etc.
Engaged in Drug Discovery-Biology research for preclinical evaluation of new chemical entities, development of cell-based assays, cloning and cell line development for expression of particular receptors by employing state-of the art recombinant technologies to be used for screening purposes.
High throughput screening of the drugs and new chemical entities emphasizing receptor mediated cell signaling using most sophisticated automated systems, robotics, and cell-based and cell-free assay techniques.
Senior Research Scientist Jun 2004 - Aug 2008
Hudson Surface Technology, Inc.
Company website: http://www.maldiplate.com
Development of a new therapeutic approach targeting diabetes, especially under the state of insulin resistance addressing insulin signaling, insulin glycation, and inhibition of protein tyrosine phosphatase 1B (PTP 1B).
Identified molecular mechanism for vanadate-induced insulin signaling in insulin-target 3T3-L1& non-target IM9 cells addressing phosphorylation of Tyr972 NPEY motif as well as Tyr1158, Tyr1162, Tyr1163 of insulin receptor, Thr308 and Ser473 of Akt, Ser9 of GSK-3ß kinase, and Ser259 Raf Kinase.
Targeting Insulin Glycation: Elucidation of molecular mechanism using proteomics tools and Surface Plasmon Resonance (SPR).
Development of MALDI-TOF-Mass Spectrometry-based proteomics tools that would have potential applications in biological and pharmaceutical research especially for the identification of biomarkers of certain diseases.
Currently, these products are on the process of patenting and commercialization. While, some others are under development.
Writing and publishing of papers as follows:
Shambhunath Bose, M. A. Farah, H.C. Jung, J. H. Lee, and Y. Kim (2007). Molecular
mechanism of bis(maltolato)oxovanadium(IV)- -induced insulin signaling in 3T3-L1
and IM9 cells: Impact of dexamethasone. Journal of Molecular Endocrinology, 38,
627–649.
M. A. Farah, Shambhunath Bose, J. H. Lee, H. C. Jung, and Y. Kim (2005). Analysis
of glycated insulin by MALDI-TOF mass spectrometry. Biochimica et Biophysica
Acta (General Subjects), 1725, 269-282.
M. A. Farah, Shambhunath Bose, and Y. Kim (2004). Analysis of molecular
interaction of glycated insulin with insulin receptor by MALDI-TOF mass spectrometry
and Surface Plasmon Resonance (SPR). Molecular & Cellular Proteomics, 3, S126.
Selected International Presentations:
R. Ghosh, Shambhunath Bose, M. Son, J. Seo, Y. Kim, J. Chang, and H. B. Lim.
Immuno-Affinity Based Detection of Small GTPases by MALDI TOF MS Using Glyco-Affi
18
MALDI Plate. 56th ASMS Conference on Mass Spectrometry & Allied Topics,
June 1 – June 5, 2008, Colorado Convention Center, Denver, Colorado, USA.
Shambhunath Bose, and Y. Kim. Oriented immobilization of monovalent antibody on
magnetic beads: An approach for a proteomics tool. 6th Annual Congress, Human
Proteomics Organization (HUPO), October 6 – October 10, 2007. COEX, Seoul,
South Korea.
M. A. Farah, H. Choi, R.P. Ghosh, Shambhunath Bose, M. Ha, and Y, Kim.
Immunoassay with glyco-specific affinity MALDI plates. 6th Annual Congress,
Human Proteomics Organization (HUPO), October 6 – October 10, 2007.
COEX, Seoul, South Korea.
M. A. Farah, J-H Lee, H. Y. Choi, Shambhunath Bose, H. B. Lim, and Y. Kim.
Preparation of antibody affinity layer on glyco-affinity MALDI plate. 55th ASMS
Conference on Mass Spectrometry, June 3 - June 7, 2007. Indiana Convention
Center Indianapolis, Indiana, USA. Poster Number: 216.
M. A. Farah, Shambhunath Bose, J-H Lee, and Y. Kim. Analysis of binding of
immobilized insulin to its receptor: Future implications. 6th Annual International
Proteomics Conference. From Bench to Clinical Application. The Korean
Human Proteome Organization (KHUPO), March 30th- March 31st, 2006, New
Millennium Building, Konkuk University, South Korea.
M. Y. Ha, J. I. Shim, Shambhunath Bose, M. A Farah, E. K. Lee, and Y. Kim.
Analysis of membrane proteins from human B lymphoblast IM-9 cells by Matrix
Assisted Laser Desorption Ionization Mass Spectrometry. 53rd ASMS Conference on
Mass Spectrometry and Allied Topics, June 5- June 9, 2005. San Antonio, TX,
USA. Poster MP25 – 403.
M. A. Farah, H.-C. Jung, Shambhunath Bose, and Y. Kim. Response of insulin
receptor to vanadate. 13th Korea-Japan Symposium on Diabetes Mellitus:
Perspectives of diabetes and metabolic syndrome. Korean Diabetes
Association. November 11th – November 12th, 2005. Hotel Grand Hilton,
Seoul, South Korea.
19
H.-C. Jung, M. A. Farah, Shambhunath Bose, and Y. Kim. Mode of interaction of
vanadate with insulin receptor. The 17th Annual Meeting of the KSMCB. Korean
Society for Molecular and Cellular Biology. October 17th – October 18th,
2005. COEX, Seoul, South Korea.
M. A. Farah, H.-C. Jung, Shambhunath Bose, R.P. Ghosh, and Y. Kim. Mode of
interaction of insulin sensitizing agents with insulin receptor. 62nd KSBMB Annual
Meeting in 2005: From Mechanism to Functions. Korean Society for
Biochemistry and Molecular Biology. May 19th – May 20th, 2005, COEX, Seoul,
South Korea.
M. Y. Ha, J. I. Shim, Shambhunath Bose, M. A. Farah, E. K. Lee, and Y. Kim.
Analysis of membrane proteins from human lymphoblast IM-9 cells by mass
spectrometry. KHUPO 5th International Proteomics Conference AOHUPO
Worksop/Symposium. The Korean Human Proteome Organization (KHUPO),
April 27th- April 29th, 2005, New Millennium Building, Konkuk University,
South Korea.
Post-Doctoral Fellow Aug 2000 - May 2004
University website: http://www.biomedicum.fi
Conducted research on cancer and apoptosis. Elucidated molecular mode of action of histone and antimicrobial peptides as apoptotic inducers in cancerous cells.
Elucidation of molecular mechanisms of action of antimicrobial peptide Plantaricin A in human leukemic T-cells.
Development of sensitive liposome-based techniques for identification and characterization of apoptotic cells.
Establishment of a model that was used to elucidate the molecular mechanism of histone- mediated apoptosis in cancerous cells.
Writing and publishing of manuscripts in the journals as follows:
H. Zhao, R. Sood, A. Jutila, Shambhunath Bose, G. Fimland, J. Nissen-Meyer, and
P.K. Kinnunen (2006). Interaction of the antimicrobial peptide pheromone Plantaricin
A with model membranes: Implications for a novel mechanism of action. Biochimica
et Biophysica Acta (Biomembranes), 1758, 1461-1474.
Shambhunath Bose, I. Tuunainen, M. Parry, O. P. Medina, G. Mancini, and P.K. J.
Kinnunen (2004). Binding of cationic liposomes to apoptotic cells. Analytical
Biochemistry. 331, 385–394.
H. Zhao, Shambhunath Bose, E. K. J. Tuominen, and P. K. J. Kinnunen (2004).
Interactions of Histone H1 with phospholipids and comparison of its binding to giant
liposomes and human leukemic T cells. Biochemistry (USA), 43, 10192-10202.
Selected International Presentations:
H. Zhao, Shambhunath Bose, E. K. J. Tuominen, and P. K. J. Kinnunen. Histone H1
and acidic phopholipids form supramolecular aggregates in the cell membrane. Eur.
Biophys. J. 32 (3), Abs. 6-10, 2003.
Shambhunath Bose, I. Tuunainen, M. Parry, O. P. Medina, and P. K. J. Kinnunen.
Labeling of apoptotic cells by cationic liposomes. 6th Beatson International
cancer Conference: Cell signaling and Cancer. July 6th- July 10th, 2003,
Glasgow, Scotland, UK.
Research Scientist Feb 1998 - Apr 2000
Company website: http://www.zyduscadila.com
Engaged in Drug Discovery research in the following areas:
Pharmacokinetic profiling of Proton pump inhibitor and other drugs.
Basic research on anti-diabetic candidates.
In vivo and in vitro efficacy, toxicity, and mode of action studies of drugs. Preclinical screening of drugs using different animal models.
Research Scientist Feb 1995 - Dec 1997
Company website: www.wockhardt.com
Engaged in Drug Discovery research.
Involved in handling major therapeutic areas including basic research on HBsAg, and Erythropoietin.
Pharmacological evaluation of anti-bacterial candidates.
In vivo and in vitro efficacy, toxicity, and mode of action studies of drugs.
Preclinical screening of drugs using different animal models.
Education
Visva-Bharati University, India 1989 - 1994
Field of study: Life Sciences
Degree: Ph.D.
Thesis title: Toxic response to group-IIB metals in rats and mice.
Visva-Bharati University, India 1986 - 1998
Field of study: Life Sciences
Degree: M.Sc.
Visva-Bharati University, India 1983 - 1986
Field of study: Life Sciences
Degree: B.Sc.
Skills
Life Sciences, Biotechnology, Molecular Biology, Biochemistry, Pharmaceuticals, Pharmacology, Drug Discovery both in academics and industries.
Manuscript writing and publications
More than 20 years of extensive experiences in R&D, drug discovery, biology.
Extensive experience in working with prime therapeutic segments: Diabetes, Obesity, and Inflammation including Neuroinflammation.
Characterization, profiling and studies of mechanism(s) of action of therapeutic candidates involving GPCR, ion channels, and insulin signaling pathways.
In vitro and in vivo preclinical screening and profiling of drug candidates, toxicological studies, structure-activity relationship studies, lead identification and optimization of candidate drug molecules.
High throughput screening of the drugs and new chemical entities emphasizing receptor mediated cell signaling using most sophisticated automated systems, robotics, and cell-based and cell-free assay techniques.
Extensive technical knowledge in omics-based studies, single nucleotide polymorphism (SNP), cloning, transfection, and gene expression using PCR, Real Time PCR, and microarray.
Detailed investigations on the influence of gut microbial-host interaction on the onset and progression of metabolic disorders at molecular levels using Real-time PCR, microarray, PCR-denaturing gradient gel electrophoresis fingerprinting, and pyrosequencing, as well as different bioinformatics tools for functional annotation and analyses of correlation, principal coordinate, and clustering.
Extensive experience in working with radioisotope-based techniques like radioreceptor assay, radioimmunoassay & radio-ligand binding assay.
Adequate exposure to fluorescence techniques, confocal laser microscopy, and fluorescence- based assays & immunohistology.
In-depth knowledge in protein isolation, purification, and characterization by using FPLC, Western Bloting, and MALDI-TOF Mass Spectrometry.
Cell culture, and cell line development using clonal selection.
Bioequivalence and metabolic studies of drugs with different chemical entities.
Fellowships
Postdoctoral Fellowship from Institute of Biomedicine, Helsinki University 2000 - 2004
Senior Research Fellowship from the Department of Biotechnology, Government of India 1993 - 1995
Prestigious Junior and Senior Research Fellowships (Dr. K.S. Krishnan DAE) from Bhabha Atomic Research Centre (BARC), Trombay, Mumbai, Department of Atomic Energy, Government of India 1990 - 1993
Junior Research Fellowship from the University Grants Commission, Government of India 1989 - 1990
Awards
Prestigious Junior and Senior Research Fellowships (Dr. K.S. Krishnan DAE) from Bhabha Atomic Research Centre (BARC), Trombay, Mumbai, Department of Atomic Energy, Government of India 1990
Grants
Clinical Microbial Analysis, Government of South Korea 2011 - 2014
New oriental drug R&D, Government of South Korea 2010 - 2013
Clinical Investigations on herbal medicines, Government of South Korea 2009 - 2011
Drug Discovery, Jubilant Biosys Limited, Bangalore India 2008 - 2009
Languages
English, Hindi, Bengali
Additional information
CONSULTANT/EXPERT
____________________________
Ex-New Product Consultant (NPC) for ‘Small Molecule Tools in Cell Biology’, Sigma-Aldrich Corporation, St. Louis, MO, USA.
Worked as an external expert on the ‘Future Trends Study of Obesity’ for Sterling Brands, Los Angeles, CA, USA.
Consultant/Member of Society of Industry Leaders, Standard & Poor's, Vista Research Inc., a division of the McGraw-Hill Companies, USA.
Expert in Pharmaceutical and Life Science Research and Manufacturing, New Drug Discovery, Therapeutic Strategy of Intota, which is a business-to-business service of Guideline, USA.
CV
Please sign in to view the CV.